All things being equal I generally disregard risks that would otherwise be consistent with other Biotech's and the market. i.e. Focus on risks that are Centric to Race and their strategy / within their control. I think the SPP has a good summary and also the independent expert report in the Prospectus when Race first listed.
For me stand-out risks, first-to-market barriers in relation to FTO is biggest concern. Secondly time to get trials wrapped up and shareholder sentiment + no major Insto or private equity support (could a MoF sell-off be worse than BG)?
General Comments / Chat, page-5381
-
- There are more pages in this discussion • 6,566 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |